drug
(linagliptin + metformin hydrochloride)
Marketedupdated 3mo agoby MSN Pharmaceuticals Inc
Approvedcommunity read0 votes
indications
investigational
Type 2 Diabetes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 20, 2026
147 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (30)
- Dec 8, 2037patentUS 12364700*PED
- Dec 8, 2037patentUS 12364700*PED
- Jun 8, 2037method-of-use (U-4224)US 12364700
- Jun 8, 2037method-of-use (U-4224)US 12364700
- Sep 6, 2033patentUS 9555001*PED
- Sep 6, 2033patentUS 9555001*PED
- Mar 6, 2033formulationUS 9555001
- Mar 6, 2033formulationUS 9555001
- Nov 21, 2030patentUS 9155705*PED4.3y
- Nov 21, 2030patentUS 9155705*PED4.3y
- May 21, 2030formulationUS 91557053.8y
- May 21, 2030formulationUS 91557053.8y
- Apr 10, 2030method-of-use (U-3854)US 119113883.7y
- Apr 10, 2030method-of-use (U-3854)US 119113883.7y
- Oct 2, 2029patentUS 10022379*PED3.2y
- Oct 2, 2029patentUS 10022379*PED3.2y
- Oct 2, 2029patentUS 9415016*PED3.2y
- Oct 2, 2029patentUS 9415016*PED3.2y
- Apr 2, 2029method-of-use (U-2339)US 100223792.7y
- Apr 2, 2029method-of-use (U-2339)US 100223792.7y
- Apr 2, 2029formulationUS 94150162.7y
- Apr 2, 2029formulationUS 94150162.7y
- Nov 4, 2027patentUS 8673927*PED1.3y
- Nov 4, 2027patentUS 8673927*PED1.3y
- Nov 4, 2027patentUS 9173859*PED1.3y
- Nov 4, 2027patentUS 9173859*PED1.3y
- May 26, 2026patentUS 8883805*PED
- May 26, 2026patentUS 8883805*PED
- Nov 26, 2025formulationUS 8883805
- Nov 26, 2025formulationUS 8883805
FDA exclusivities (4)
- Dec 20, 2026PEDPediatric (6mo bonus)147d
- Dec 20, 2026PEDPediatric (6mo bonus)147d
- Jun 20, 2026M-295Method (3y)
- Jun 20, 2026M-295Method (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that